Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy

As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning hopes on a smooth finish—and possibly, a result in line with Novartis’ spinal muscular atrophy gene therapy Zolgensma.